

# The Medical Letter®

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

Volume 49 (Issue 1265)  
July 16, 2007

[www.medicalletter.org](http://www.medicalletter.org)

### IN BRIEF

---

#### **Anaphylaxis with Omalizumab (*Xolair*)**

The FDA has received new reports of serious and life-threatening hypersensitivity reactions to omalizumab (*Xolair* – Genentech), a monoclonal anti-IgE antibody injected subcutaneously for treatment of asthma ([Med Lett Drugs Ther 2003; 45:67](#)), and has added a black-box warning to the package insert.

Postmarketing reports submitted to the FDA included 124 reports of anaphylaxis among an estimated 57,300 patients (0.2%) who might have been treated with the drug between June 2003 and December 2006. Anaphylaxis occurred after the first dose of *Xolair* in 39% of cases, after a 2nd dose in 19%, after a 3rd dose in 10% and after subsequent doses in the rest; one case occurred after 39 doses (19 months of continuous therapy) when treatment was restarted after a 3-month gap. Most cases (59%) occurred within 2 hours of the injection, but 32% occurred later, up to 4 days after the injection. No deaths have been reported ([www.fda.gov/cder/drug/infopage/omalizumab](http://www.fda.gov/cder/drug/infopage/omalizumab)).

Use of omalizumab should be limited to patients with severe asthma that is not adequately controlled by other drugs and has a clear allergic component. Patients should be observed for 2 hours after injection in a setting where anaphylaxis can be diagnosed and treated promptly and should carry an epinephrine autoinjector (*EpiPen*; *Twinject*) for a few days following an injection.

**Coming Soon in *The Medical Letter*:**

Reducing Intake of Trans Fatty Acids  
*Lybrel* — A New Contraceptive Pill  
Lapatinib (*Tykerb*) for Breast Cancer

**Coming Soon in *Treatment Guidelines*:**

Drugs for Allergic Disorders — August 2007  
Drugs for Sexually Transmitted Infections —  
September 2007  
Drugs for COPD — October 2007

The Medical Letter®  
On Drugs and Therapeutics

**EDITOR:** Mark Abramowicz, M.D.

**DEPUTY EDITOR:** Gianna Zuccotti, M.D., M.P.H., Weill Medical College  
of Cornell University

**EDITOR, DRUG INFORMATION:** Jean-Marie Pflomm, Pharm.D.

**CONTRIBUTING EDITOR, DRUG INTERACTIONS:** Philip D. Hansten, Pharm.D.,  
University of Washington

**ADVISORY BOARD:**

**Jules Hirsch, M.D.,** Rockefeller University

**David N. Juurlink, BPhm, M.D., PhD,** Sunnybrook Health Sciences Centre

**James D. Kenney, M.D.,** Yale University School of Medicine

**Richard B. Kim, M.D.,** University of Western Ontario

**Gerald L. Mandell, M.D.,** University of Virginia School of Medicine

**Hans Meinertz, M.D.,** University Hospital, Copenhagen

**Dan M. Roden, M.D.,** Vanderbilt University School of Medicine

**F. Estelle R. Simons, M.D.,** University of Manitoba

**Neal H. Steigbigel, M.D.,** New York University School of Medicine

**EDITORIAL FELLOWS:**

**Vanessa K. Dalton, M.D., M.P.H.,** University of Michigan Medical School

**Eric J. Epstein, M.D.,** Albert Einstein College of Medicine

**DRUG INTERACTIONS FELLOW:** Emily Ung, BScPhm, Children's Hospital of  
Western Ontario

**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard

**ASSISTANT EDITORS:** Cynthia Macapagal Covey, Tracy Shields

**MANAGING EDITOR:** Susie Wong

**PRODUCTION COORDINATOR:** Cheryl Brown

**VP FINANCE & OPERATIONS:** Yosef Wissner-Levy

Founded in 1959 by

Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The content of The Medical Letter is controlled by the Editor, who declares no conflict. The members of the Advisory Board are required to disclose any potential conflict of interest.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

**Subscription Services**

**Mailing Address:**

The Medical Letter, Inc.  
1000 Main Street  
New Rochelle, NY 10801-7537

**Customer Service:**

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
Web Site: [www.medicalletter.org](http://www.medicalletter.org)  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**

To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**

1 year - \$89; 2 years - \$151;  
3 years - \$214. \$44.50 per year for  
students, interns, residents and  
fellows in the US and Canada.  
CME: \$44 for 26 credits.

**E-mail site license inquiries to:**

[info@medicalletter.org](mailto:info@medicalletter.org) or call  
800-211-2769 x315.

Special fees for bulk subscriptions.  
Special classroom rates are avail-  
able. Back issues are \$12 each.  
Major credit cards accepted.

Copyright 2007. ISSN 1523-2859